Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin Combinations in R/R FL and DLBCL
NCT02600897Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 2 trial of polatuzumab vedotin in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Mar 2016; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02600897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02600897.